Canntab Therapeutics IN THE NEWS (Equity.Guru) – Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale
BYCHRIS PARRY 01/21/2021 IN CBDS, EDIBLES, EXPORTS, FEATURED CONTENT, HEALTH-MEDICINE, MUSHROOMS, PARRY, PHARMACEUTICALS, SHROOM BOOM If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught. In a sector where the law says you’re not allowed to market yourself, low prices offer one of the few ways to grow market share while also kicking off a race to the bottom. Premium suppliers would suggest they have an advantage, but since they can’t advertise that premium status in a meaningful way, they have to rely on word